The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...
Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback